Former Neuralink Chairman Now Invests Synchron
It is the first company to start testing brain chips in humans
Max Hodak, who is the former president of Neuralink, announced through his social networks that he has invested in the company's competitor: Synchron.
In July 2021, the Synchron company announced that it already had the permits from the United States Food and Drug Administration, better known as the FDA, to begin carrying out the necessary tests for the future implementation of brain chips in humans.
The Food and Drug Administration (FDA) is the United States Government agency responsible for regulating food, drugs, cosmetics, medical devices, biological products, and blood products.
In December the company announced that one of its human test patients, a man with amyotrophic lateral sclerosis, had used the device implanted in his brain to write a thoughtful tweet that read, "Hello World! Short tweet. Monumental progress." ".
hello, world! Short-tweet. Monumental progress.— Thomas Oxley (@tomoxl) December 23, 2021
On the one hand, Neuralink is working on a device that it wants to embed in people's brains to monitor and potentially stimulate brain activity. On the other hand, Synchron is developing a neural interface device, which accesses the brain through blood vessels.
“Accessing the brain through blood vessels is an elegant idea, and after 10 years of work @synchroninc recently announced results from their first human patients; a great achievement. I'm excited to get involved as an investor as they move from the bank to bed," wrote Max Hodak on his Twitter account.
Accessing the brain via blood vessels is an elegant idea, and after 10y of work @synchroninc recently announced results from their first human patients; a huge accomplishment.— Max Hodak (@maxhodak_) February 4, 2022
I'm excited to get involved as an investor as they go from bench to bedside.https://t. co/Lwo0M3T46T